RYSE Asset Management, a United Kingdom-based global financial investment firm, has listed Vigilent Labs as an investment opportunity. RYE Asset Management invests in early-stage health data technology firms that demonstrate promising growth on a global scale. RYSE connects high-potential healthcare firms with established global distribution partners.
The announcement came as Vigilent Labs announced the relocation of its Headquarters from the Charleston Navy Yard to 3860 Faber Place Drive, North Charleston. The 10,000 square feet of office and light manufacturing space will serve as its headquarters and East Coast manufacturing operations site to streamline with its international partners, SeroClinix and UniBiosciences (UBS), and meet the increasing demand for COVID-19 Antigen and Antibody test kits worldwide. Vigilent Labs is an advanced health and medical technology company providing solutions for the detection and identification of health and bio threats and diseases.
Established in 2019, the company has an internationally renowned team of medical scientists, healthcare physicians, and business executives. The company offers FDA/EUA approved COVID-19 (and its variants) test kits, Influenza A, Influenza B, and Norovirus, and more.
Vigilent Labs’ technology is unique, because test results can be loaded onto their proprietary v. Labs Platform© (VLMS), and leverage its v. Resolute Reader, lab in your hand that provides rapid and accurate screening results.
John Falk, Founder & President of Vigilent Labs said, “We are beyond thrilled to have been listed by the prominent financial firm RYSE Asset Management; while, at the same time, our Leadership Team and Board has made the strategic decision to locate closer to the Charleston Airport opening other logistical channels for the current and future production and distribution of our test kits and devices throughout the United States and around the globe.”
To learn more information: www.vigilentlabs.com
To learn more information: www.ryseam.com